ERBB2 and breast carcinoma: In a study of transtuzumab deruxtecan (TD) for the treatment of HER2-positive breast cancer, the overall incidence of platelet count decline was 21.2%; the incidence of grade 3 was 3.8%, and grade 4 was 0.5% (Modi et al., 2020).